China is home to one-tenth of the world's nonhuman primates, with about 20 native species and an abundance of rhesus macaques (Macaca mulatta). Since India banned exports of all primates in 1977, China has steadily increased the number of monkeys that it exports to about 20,000 annually today. Although all exported monkeys are supposed to have been bred and raised in breeding facilities and although the government has banned the capture of wild monkeys, there has been a decline in China's wild macaque population from ?254,000 in 1998 to ?100,000 in 2003, according to field surveys. Alarmed by this trend and citing a 2002 US National Academy of Sciences report discussing the shortage of rhesus monkeys for research (http:// dels.nas.edu/ilar_n/ilarjournal/44_3/ v44n03workshop.pdf), some Chinese scientists have urged the government to designate the rhesus macaque a "national strategic resource" and have called for an export ban. Although Chen Zhu, vice president of the Chinese Academy of Sciences (CAS), does not support an export ban, he agrees that "we must protect this resource." Chen points out that "conservation efforts should involve the protection of habitats in southwest China, which needs the support from other ministries and local governments." For its part, CAS plans to boost China's biomedical research capabilities and "indigenous innovation" (the government's latest buzzword) by capitalizing on the natural availability of rhesus monkeys.
The Heavyweight Champ
As a first step, CAS injected 10 million yuan (about $1.3 million) into renovating an old monkey facility at China's contribution to primate research is no longer limited to supplying monkeys to scientists abroad. With an abundance of wild rhesus macaques, low labor costs, and a nonhostile environment for animal research, scientists are finding that China is the place to be for research using macaques as models of human disease. to collaborate with local researchers and scientists from the French National Institute for Agricultural Research on cloning related topics, such as monkey embryo reprogramming, differentiation of macaque stem cells into neural progenitor cells, and programmed expression of the nonhuman primate genome during embryonic development.
Other research at KPRC includes comparative primate genomics, led by principal investigator Su Bing, which received a boost with the publication this April of the complete rhesus macaque genome sequence. Su's group focuses on the genetic mechanisms of human evolution by comparing gene expression profiles in human and nonhuman primate brains, in particular the prefrontal cortex, to seek out genes that have undergone adaptive changes during evolution. Su claims to have one of the world's largest rhesus brain tissue collections. He also collaborates with other KPRC labs to study mechanisms of viral infection, including adaptive evolution of the gene encoding TRIM5α, which restricts infection of nonhuman primate immune cells by HIV-1.
KPRC is also home to an "overseas research team," a group of expatriate scientists who collaborate with colleagues back in China through a special program funded by CAS. The team includes Xiao-Ning Xu and Xin Lu, based in Europe, and two US-based researchers, YouWen He and Yufang Shi. According to team leader Xu, the low cost of primate research in China is a definite attraction. "Primate research in Europe is very expensive, at least ten times more than in China," explains Xu, whose research on HIV and avian influenza vaccines needs large numbers of animals "to show effect."
Another team member, Duke University researcher He, is trying to establish the tree shrew as an animal model for chronic hepatitis B virus (HBV) infection. HBV is a serious problem in China, with about 10% of the population carrying the virus. Even though both the chimpanzee and tree shrew are susceptible to acute HBV infection, there is currently no available animal model for chronic infection. Twice a year, He travels to KPRC to work on tree shrews, which are bred at this facility.
Monkey Models of Human Disease
In addition to KPRC, there are a number of other primate research centers in China. Alex Zhang is one of the first expatriate Chinese scientists to have seen an opportunity in primate research back home. After spending 6 years as a research associate at Stanford University studying neural development in mice, Zhang returned to China in 2001 to head the Cell Therapy Center at the Beijing Institute of Geriatrics, switching his research from rodents to nonhuman primates. In 2003, together with his longtime collaborator Piu Chan, a neurologist also recently returned from the United States, he founded the company Wincon TheraCells Biotechnologies, which aims to develop cell-based therapies for treating neurological and other diseases. The partners set up a primate research laboratory on land leased from Weimei Biotechnology, a monkey breeding center in Nanning, Guangxi province. The center annually breeds about 2000 cynomolgus macaques (Macaca fascicularis), a close relative of the rhesus macaque, and exports about 1500 of them each year. "It's very convenient; we can buy monkeys right outside our door," says Zhang.
With support from the Chinese government (10 million yuan over 5 years) as well as grants from private investors and foundations, Wincon is developing monkey models of human diseases, including Parkinson's disease, Alzheimer's disease, and diabetes. In collaboration with the Parkinson's Institute in Sunnyvale, California, Wincon researchers will use 115 monkeys with drug-induced Parkinson's disease for "parallel experiments, letting scientists from different labs apply various experimental therapeutic methods on the same type of disease model so that the outcome can be compared," says Zhang. Wincon is also developing a cell-based therapy for type I diabetes using a monkey model in which pancreatic β cells are killed with the drug streptozotocin. Zhang's group has isolated and characterized pancreatic progenitor cells in both healthy and diabetic monkeys and plans to treat diabetic monkeys with autologous transplants of these progenitor cells after expansion in culture. Screening of large numbers of older monkeys that, like humans, spontaneously develop type II diabetes as they age is also underway, and presymptomatic monkeys with elevated blood sugar levels have been identified. "We are keeping these monkeys as we develop a disease model for type II diabetes. They may be useful for drug testing in the future," explains Zhang. In June of 2006, Wincon became the first, and so far the only, primate facility in China to receive AAALAC accreditation. "Alex's lab is very enabling for translational medicine and very attractive to Western scientists," comments Theo Palmer, a neurobiologist at Stanford University, who recently visited Wincon.
Other researchers are also working with older monkeys as models of aging-related diseases in humans. For example, scientists at Beijing University's Institute of Molecular Medicine (Beida-IMM), founded in 2005 with 80 million yuan from the university, are collaborating with Massachusetts General Hospital (MGH) in Boston, Massachusetts, to study cardiovascular disease. "We are screening older rhesus macaques for metabolic syndrome including diabetes, insulin resistance, obesity, high blood pressure, hyperlipidemia, all of which increase the risk for cardiovascular disease," explains Paul Huang, director of the Cardiac Metabolic Syndrome Program at MGH and a leader of the collaboration.
Originally, Huang and his colleagues considered establishing their own rhesus colony near Shenzhen in southern China, where the climate would allow the monkeys to live outside throughout the year. The
Cell 129, June 15, 2007 ©2007 Elsevier Inc. 1035 municipal government supported the idea and was willing to make available a self-contained small mountain on the city's outskirts for 500 to 1000 free-roaming rhesus macaques. The colony, dubbed "monkey mountain," would allow development of "our own source for research. We can follow the monkeys over time and do longitudinal studies," says Huang. But the idea has been shelved for now because taking care of this free-roaming monkey colony would divert money and manpower away from research efforts in Beijing.
Instead, Beida-IMM is spending 5 million yuan to add a new primate wing to the university's existing animal facility. Researchers have screened several hundred older rhesus monkeys at breeding facilities throughout China and have found more than 60 animals with metabolic syndrome, which they are moving to Beijing for further study. Beijing University plans to obtain AAALAC accreditation for its monkey facility and will submit their application this summer. "I think pharmaceutical companies will feel more comfortable with AAALACaccredited facilities because that means the standard of care is the best available," says Huang, whose collaboration with Beida-IMM is partly supported by a gift from Roche to MGH.
Although most foreign scientists collaborate with Chinese colleagues to do monkey research, a few have struck out on their own. Erwan Bezard, an INSERM researcher at Université Bordeaux, France, started going to China in 1999 while a postdoctoral fellow. "European labs do not have enough monkeys for my work," he says, noting that he needs a large number of animals for statistical analysis. Given that China is the largest producer of rhesus macaques, Bezard moved some of his research to Beijing, renting lab space first from a monkey breeding facility and then from the Institute of Laboratory Animal Research at the Chinese Academy of Medical Sciences (CAMS). Bezard travels to China every 6 weeks, spending 6-10 days there each time. He supports his monkey experiments in China with grants from the European Union and private foundations and ships the brains and other tissues back to Europe for postmortem analysis. One project, funded by the Michael J. Fox Foundation in the United States, involves treating L-DOPA-induced dyskinesias in macaques with Parkinson's disease with a partial agonist of the dopamine D 3 receptor.
In addition to his basic research, Bezard recently joined forces with a British company, Motac Neuroscience, using his Beijing lab and access to monkeys for contract research with pharmaceutical companies to test drugs for treating movement disorders. "We are, I believe, the only company in the world to work exclusively with second generation of bred animals; they are not inbred, but their quality is more controlled and their entire history is known," says Bezard. Most of the rhesus macaques and all of the cynomolgus monkeys Bezard uses come from breeding facilities in southern China.
Monkey Welfare
Some outsiders point to the lack of laws for laboratory animal use and care in China as a potential problem for doing primate research there, but Chinese researchers counter that they voluntarily follow high standards. Many of the new generation of primate researchers in China have studied in the United States or Europe and are collaborating with colleagues abroad. They understand the importance of adopting international standards in order for their work to be accepted by international peers. They are the ones who push the government to establish regulations concerning animal welfare, sometimes at odds with the general public.
When the Beijing municipal government released a 2004 draft of an animal welfare law on its website for public comment, the reaction was so overwhelmingly negative that the draft was withdrawn 2 days later. Many Chinese criticized the proposed law for going too far and not being realistic. There are 135 million Chinese (about onetenth of the population) living on less than $1 a day, which the World Bank defines as abject poverty. In comparison, "monkeys listen to music, have toys to play with, and drink purified water" in Wincon's AAALAC-accredited lab, according to Zhang. The 900 million rural Chinese who cannot afford basic medical care won't be able to benefit from the millions of yuan spent on research to find treatments for Parkinson's disease, diabetes, and cardiovascular disease.
But on the whole, "China is more supportive of this kind of work [primate research] because improving human health comes first," says Bruce Lahn, a geneticist and an HHMI investigator at the University of Chicago, who set up a primate research lab in 2002 at the Jiufo monkey breeding facility in Guangzhou, the city where Lahn's collaborators are based. Lahn set ambitious goals for his lab "to generate transgenic, maybe even knockout monkey models for human diseases and to use primates both as a source and model to study stem cells, including embryonic stem cells." But he acknowledges that progress has been slow, partly because of insufficient funding.
Even though the cost of obtaining and maintaining monkeys in China may be low by Western standards, it is still high for Chinese researchers. Zhou Zhuan, a biophysicist at Beida-IMM who is leading the institute's effort for AAALAC accreditation, estimates that to maintain one monkey at their facility costs about 25,000 yuan per year. "Chinese monkeys are far more expensive than we had imagined," concedes Zhou. He adds that when conditions meet international standards, the associated costs will also approach international levels. Wincon's Zhang agrees: "From our experience of getting AAALAC accreditation, we realize that the cost of maintaining a monkey at high standards is not that much less in China than elsewhere."
Another concern is that demand for cynomolgus macaques is driving smuggling across China's southern border. Cynomolgus monkeys are not native to China, but come from southern Indochina. They can be bought cheaply in Vietnam, for instance, and then can be sold in China for ten times their purchase price. The number of monkeys being smuggled into China is difficult to track, but customs officials in Guangxi busted two smuggling operations last summer, resulting in the arrest of nine people and the rescue of 197 live cynomolgus monkeys at the Vietnamese-Chinese border.
"Biomedical research in nonhuman primates is still new in China," says CAS vice president Chen. "We need international collaboration in many aspects, not the least in borrowing from international standards for ethical treatment of lab animals." Chen emphasizes that CAS is formulating rules for using animals in research as part of the ambitious plan of building a network of primate research groups across China using KPRC as the platform for sharing this precious resource.
